Schering Claritin-D 24-hour swallowing difficulty addressed anew in July 23 "Dear Doctor" letter.
SCHERING CLARITIN-D 12-HOUR MAY BE USED IN PATIENTS WITH SWALLOWING DIFFICULTY who should not receive the 24-hour version of the loratadine/pseudoephedrine product, the company says in a July 23 "Dear Doctor" letter to prescribers. "For these patients, you may want to consider prescribing Claritin-D 12-hour (5 mg loratadine/120 mg pseudoephedrine sulfate, USP) extended-release tablets instead of Claritin-D 24-hour," the letter states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth